Novan, Inc. (NOVN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.3300 |
| Open | 2.3300 |
| Bid | 2.2000 x 1300 |
| Ask | 2.3700 x 800 |
| Day's Range | 2.2700 - 2.3300 |
| 52 Week Range | 2.1500 - 10.5800 |
| Volume | |
| Avg. Volume | 117,566 |
| Market Cap | 43.277M |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7620 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.40 |
- GlobeNewswire
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct offering priced at-the-market under Nasdaq rules with an institutional investor of an aggregate of (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompanying
- American City Business Journals
Novan preps to seek FDA approval for lead drug as competitor stumbles
A Durham-based pharmaceutical company plans to raise $15 million as it prepares to seek regulatory approval for its treatment for a viral skin infection.
- GlobeNewswire
Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules, (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompa
